Augmentation of Maxillary Horizontal And Vertical Bone Deficiency Using Mineralized Plasmatic Matrix

Not Applicable

• Conditions: Alveolar Ridge Abnormality of Maxilla
• Interventions: Procedure: Augmentation

• Registration Number: NCT03757195
• Lead Sponsor: Cairo University

Brief Summary

A new technique of grafting introduce called Mineralized plasmatic matrix. This technique can be used in grafting in anterior zone giving a good results and bone substitution occur using allograft or xenograft.

The bone graft have a good consistency when it mixed with plasma give easy application, strength and stability of the graft. Also plasma rich with CGF (Cellular growth factors).

Detailed Description

Patients suffering from anterior maxillary vertical and horizontal bone loss will be treated using a xeno-graft mixed with the same patient plasma that extracted from his own blood during the operation this graft will be stabilized by collagen membrane and surgical tags.

Patients will be follow up for 6 months to measure amount of bone loss of the xeno-graft during this period post operative using C.B.C.T

Study Timeline

• Study First Submitted: 2017-11-27
• Status Verified: 2018-11
• Study Start: 2018-11-15
• Study First Submitted QC: 2018-11-27
• Last Update Submitted: 2018-11-27
• Study First Posted: 2018-11-28
• Last Update Posted: 2018-11-28
• Primary Completion: 2020-07-29
• Study Completion: 2020-10-25

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Age: from 20 to 40 years old
• no history of previous grafting.
• no History of previous implant placement
• Medically Free e.g no debilitating diseases

Read More

Exclusion Criteria

• Smoker patients.
• Alcoholic patients
• Pregnant.
• Drug Abusers.
• Hypertensive , Diabetic, having Problems or disease in Kidney and/or liver.
• Thyroid Disease.
• Problem in Vit.D absorption or in calcitonin hormone secretion.
• History of blood transfusion or donating blood less than 4 months.
• Patient under Corticosteroid therapy.
• Neurologicaly unstable patients.
• History of radiotherapy or chemo-therapy.
• Patient undergo Spect C.T Scan less than 4 Months .

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
augmentation by xenograft	Augmentation	xenograft mixed with plasma extracted from blood

Primary Outcome Measures

Name	Time	Method
amount of bone loss	change from baseline at 6 months	amount of bone loss after xenograft by CBCT

Trial Locations

Locations (2)

Cairo Univerisity; 🇪🇬 Cairo, Egypt

Cairo University; 🇪🇬 Cairo, Egypt